Sign inStart free

Health Care · Pharmaceutical Preparations

NVCT Nuvectis Pharma, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 187555845 filings
Russell 2000
Follow NVCT for alertsAsk AI about NVCT

NVCT at a glance

Nuvectis Pharma, Inc. (NVCT, SEC CIK 1875558) filed its latest 10-K annual report on February 11, 2026, a 10-Q quarterly report on August 4, 2026, an 8-K current report on August 21, 2026 and Form 4 insider filings as recently as August 5, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • As of June 30, 2026, 17 institutional investment managers tracked by SignalX reported holding Nuvectis Pharma, Inc. (NVCT) shares worth $49.3 million in 13F-HR filings.
  • The most recent insider open-market purchase reported on Form 4 was by Mosseri Marlio Charles on June 30, 2026 of 50,000 shares at $18.32 per share.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
17 funds
$49.3M · +1 vs prior quarter
Latest 8-K
Aug 21, 2026
Item 8.01

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Jun 30, 2026

Management Discussion & Analysis

  • Revenue $0, unchanged YoY; no revenue generated since inception
  • Operating loss $7.197M vs $6.595M YoY; operating margin not meaningful with zero revenue
  • R&D expenses $4.684M, up 30% YoY; NXP900 clinical and manufacturing costs up $0.8M
  • Cash $22.2M at June 30; operating cash use $11.042M vs $7.541M YoY
  • July offering net proceeds approximately $106.3M; funding expected through at least next 12 months

Risk Factors

  • Newly added tariff risk, triggered by U.S. trade-policy changes, potentially increasing raw-material, reagent, and laboratory-equipment costs
  • Most material financial risk: accumulated deficit of $112.8 million through June 30, 2026, with continued losses expected
  • Regulatory disruption risk from FDA or SEC funding shortfalls and government shutdowns delaying approvals or public-market access
  • Clinical-development risk: NXP800 development ceased in platinum-resistant ARID1a-mutated ovarian carcinoma after preliminary Phase 1b analysis
  • Operational supply-chain risk from tariffs or trade restrictions disrupting availability of clinical materials and logistics

AI summary of the NVCT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Aug 21, 2026Full analysis →

Item 8.01: Other Events

  • New ATM program enables Nuvectis to sell common shares opportunistically through Jefferies
  • $200 million shelf registration expands potential financing capacity across securities
Filed Aug 4, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q2 2026 results and corporate update announced for quarter ended June 30, 2026
  • Press release furnished as Exhibit 99.1, containing the substantive financial and operating details

Item EX-99.1: Item EX-99.1

  • Q2 net loss $7.0M versus $6.3M; R&D rose to $4.7M from $3.6M as development activity accelerated
  • July follow-on offering raised $115M gross, extending stated cash runway into 1H 2029 but increasing share dilution risk
Filed Jun 30, 2026Full analysis →

Item 8.01: Other Events

  • Nuvectis launched and priced a securities offering on June 29, 2026
  • Offering likely creates potential dilution or financing proceeds for NVCT shareholders

Item 1.01: Entry into a Material Definitive Agreement

  • $100 million gross equity offering: 5,000,000 shares at $20.00 each
  • Approximately $93 million net proceeds, increasing to approximately $107 million if the option is fully exercised

Item EX-99.1: Item EX-99.1

  • Proposed underwritten public offering of common stock, creating potential dilution for existing shareholders
  • Underwriters granted 30-day option for up to 15% additional shares, potentially increasing dilution

AI summaries of NVCT 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for NVCT

Don't miss the next NVCT filing

  • Alerts as it files. A push when NVCT files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut NVCT, by share count.
  • Ask anything. An AI agent that reads every NVCT filing and answers with sources.
Follow NVCT for alertsAsk AI about NVCT
Compare plans →

NVCT alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Carson Michael J.AAug 3, 2026-
Mosseri Marlio CharlesBuyJun 30, 2026$18.32
BENTSUR RONBuyJun 30, 2026$20.00
Sanchez JuanAJun 11, 2026-
Hoberman KennethAJun 11, 2026-
Kaplan Matthew L.AJun 11, 2026-
Oliviero James F IIIAJun 11, 2026-
BENTSUR RONAJan 6, 2026-
Insider trades across all companies →Which insider buys matter →

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Operating Income-$22.9M-$19.8M-$27.6M
Net Income-$22.3M-$19.0M-$26.4M
Balance Sheet
Total Assets$19.2M$18.6M$31.7M
Equity$12.2M$9.7M$18.4M
ROE-182.4%-195.6%-143.6%
Per Share
EPS$-1.43$-1.11$-1.32
Cash Flow
Operating CF-$16.0M-$12.2M-$16.0M

Source: XBRL data in Nuvectis Pharma, Inc. (NVCT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q2 2026

Aggregate NVCT share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
NVCT shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q2 202617$49.3M
Q1 202616$15.7M
Q4 202514$16.0M
Q3 202516$11.4M
Q2 202516$13.0M
Q1 202510$7.7M
Q4 20245$2.3M
Q3 20245$889,000
Position changes: Q1 2026 → Q2 2026
Top Buyers
Top Sellers
New Positions
Closed Positions
None this quarter.

Source: 13F-HR filings on SEC EDGAR (aggregated from 99 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

NVCT filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KAug 21, 2026Analysis-
SC 13GAug 6, 2026-
4Aug 5, 2026--
8-KAug 4, 2026Analysis-
10-QAug 4, 2026Analysis
4Jul 1, 2026--
4Jul 1, 2026--
8-KJun 30, 2026Analysis-
8-KJun 29, 2026Analysis-
8-KJun 23, 2026Analysis-
8-KJun 12, 2026Analysis-
4Jun 12, 2026--
4Jun 12, 2026--
4Jun 12, 2026--
4Jun 12, 2026--
8-KMay 5, 2026Analysis-
10-QMay 5, 2026Analysis
8-KFeb 11, 2026-
10-KFeb 11, 2026-
4Jan 9, 2026-
4Jan 9, 2026-
4Jan 9, 2026-
4Jan 9, 2026-
10-QNov 4, 2025Analysis
10-QAug 5, 2025-

Related Health Care companies

All Health Care →

NVCT SEC filings: frequently asked questions

Which institutions hold NVCT stock?

As of June 30, 2026, the largest Nuvectis Pharma, Inc. (NVCT) holders among the 13F filers tracked by SignalX were BlackRock ($18.4 million), Vanguard Capital Management LLC ($16.0 million), State Street Corp ($4.6 million), Northern Trust ($2.7 million), Vanguard Portfolio Management LLC ($2.2 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What did NVCT report in its latest 8-K?

Nuvectis Pharma, Inc. (NVCT) filed an 8-K on August 21, 2026 reporting Item 8.01 (Other Events). New ATM program enables Nuvectis to sell common shares opportunistically through Jefferies.

What are the latest NVCT SEC filings?

Nuvectis Pharma, Inc. (NVCT) filed its latest 10-K annual report on February 11, 2026, a 10-Q quarterly report on August 4, 2026, an 8-K current report on August 21, 2026 and a Form 4 insider filing on August 5, 2026.

What is NVCT's SEC CIK number?

Nuvectis Pharma, Inc. (NVCT)'s SEC Central Index Key (CIK) is 1875558. EDGAR lists every NVCT filing under that number.

Ask anything about NVCT

The research agent reads NVCT's filings, financials, insider trades and 13F holders, then answers with sources.

Start free